HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR’s 2019 Priorities A Botanical Garden; AHPA To Stay Tuned In

This article was originally published in The Rose Sheet

Executive Summary

The American Herbal Products Association vows to stay abreast of Cosmetic Ingredient Review activities, with ingredients of importance to its members sprinkled throughout the group’s 2019 priority list.

You may also be interested in...



CIR Expert Panel Wraps Five Ingredient Safety Assessments, Finalizes 2022 Priorities

Meeting virtually on 13-14 September, Cosmetic Ingredient Review's independent expert panel issued final safety assessments for red algae, tea tree and three other ingredients/groups, as well as eight tentative reports and five insufficient data announcements. The group also finalized its review priorities for 2022.

CIR Tackles Growing Natural Workload Against Backdrop Of Widely Held Safety Assumptions

CIR’s Expert Panel reached tentative safe conclusions for a number of naturally derived ingredients at its December meeting, while identifying data deficiencies for others. In his post-meeting report, Executive Director Bart Heldreth highlights recent commentaries in scientific journals defying the notion that natural is necessarily safe and lauding CIR as the preeminent ingredient safety authority.

FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD

Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.

Related Content

Topics

UsernamePublicRestriction

Register

RS121662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel